NASDAQ's CUR just appointed TPIY Member to Board
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported):December 20, 2017 (December 18, 2017)
Neuralstem, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware001-3367252-2007292(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)
20271 Goldenrod Lane, 2nd Floor, Germantown, Maryland 20876(Address of Principal Executive Offices) (Zip Code)
(301) 366-4960
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 18, 2017, Neuralstem, Inc. (the “Company”) was informed by Tianjin Pharmaceuticals Group International Holdings Co., LTD (“Tianjin”) that Xi Chen, Ph.D. is being appointed to replace Zhang Zhuo as the director appointee of the Company’s Series A 4.5% Convertible Preferred Stock (“Series A Stock”). Tianjin is the sole shareholder of the Company’s Series A Stock. Dr. Chen will serve as a Class III director until the Company’s 2020 annual shareholder meeting or until such time as he resigns or is removed .
There are no family relationships among Dr. Chen and any of our executive officers or directors.
As compensation for his service on the board of directors, Dr. Chen will participate in the Company’s non-executive board compensation policy as described in the Company’s Current Report on Form 8-K filed on June 27, 2017.
A copy of the press release announcing Dr. Chen’s appointment is attached to this report as Exhibit 99.01.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description
99.01 Press Release Dated December 20, 2017
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Neuralstem, Inc. Date: December 20, 2017By: /s/ Richard Daly Richard Daly Chief Executive Officer
INDEX OF EXHIBITS
Exhibit No. Description 99.01 Press Release Dated December 20, 2017
Exhibit 99.01
New Member appointed to the Board of Directors of Neuralstem
GERMANTOWN, Md., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that Xi Chen, Ph.D., has been appointed to its Board of Directors, effective immediately. Dr. Chen was appointed by Tianjin to replace Zhang Zhuo as the director appointee of the Series A Convertible Preferred Stock.
“It is our pleasure to welcome Dr. Chen to the Board of Directors,” said Rich Daly, Chairman and CEO. “Dr. Chen comes to us with years of therapeutic development and administrative expertise, and the contributions and guidance that he has to offer will be highly valuable to the future of the Company.”
Dr. Chen has served as the Assistant General Manager of Manufacture, Equipment, and Administration at Tianjin Kinnovata Pharmaceutical since 2014. He also served as the Deputy Director of the Marketing Department at Tianjin Pharmaceutical Holdings since 2012. Previously, Dr. Chen was the Executive Vice General Manager of Tianjin Lights Medical Device Co., and a Research Associate, Lab Manager at the University of Ottawa, and Anesthesiologist at Tianjin Union Hospital.
Dr. Chen. holds a PhD in Enterprises Management, a Master’s Degree in Molecular Biology from University of Ottawa, and a Clinical Bachelor’s Degree from Tianjin Medical University.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. NSI-189 is a small molecule in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke. NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell technology.
Cautionary Statement Regarding Forward Looking Information
This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2016, and Form 10-Q for the three and nine months ended September 30, 2017, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.
Contact:
Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
kimberly@argotpartners.com
AI
